These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23427641)

  • 1. [Co-expression of estrogen receptors and Her2/neu in breast cancer. Neoadjuvant chemotherapy sentinel lymph node and hormonotherapy].
    López Carpintero N; Sánchez Méndez JI; de Santiago García JI
    Ginecol Obstet Mex; 2012 Nov; 80(11):720-4. PubMed ID: 23427641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sentinel lymph node biopsy after neo-adjuvant chemotherapy in breast cancer.
    Stell VH; Flippo-Morton TS; James Norton H; White RL
    Breast J; 2011; 17(1):71-4. PubMed ID: 21129099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of neoadjuvant chemotherapy on estrogen and progesterone receptors and P53 and CerbB-2 in breast cancer].
    Bao G; Yang DQ; Zhou B; Liu P; Wang S; Cheng L
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(40):2843-5. PubMed ID: 18167290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy.
    Pecha V; Kolarik D; Kozevnikova R; Hovorkova K; Hrabetova P; Halaska M; Sottner O; Trnkova M; Petruzelka L; Kolarova H
    Cancer; 2011 Oct; 117(20):4606-16. PubMed ID: 21437896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy.
    Buchholz TA; Huang EH; Berry D; Pusztai L; Strom EA; McNeese MD; Perkins GH; Schechter NR; Kuerer HM; Buzdar AU; Valero V; Hunt KK; Hortobagyi GN; Sahin AA
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1337-42. PubMed ID: 15275718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of neoadjuvant chemotherapy on estrogen and progesterone receptors and HER-2 in breast cancer].
    Zhao J; Wu YL; Wang YD; Zhao GR; Wang J
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Dec; 24(12):1437-9. PubMed ID: 15604081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer].
    Mátrai Z; Tóth L; Polgár C; Láng I; Gõdény M; Sinkovics I; Horváth Z; Bidlek M; Udvarhelyi N; Bartal A; Sávolt A; Ujhelyi M; Kásler M
    Magy Onkol; 2011 Jun; 55(2):73-84. PubMed ID: 21655472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A perimenopausal woman with a small, ER/HER2-positive, node-negative breast cancer.
    Brooks G; Borges V; Singh M; Rabinovitch R; Finlayson C; Elias A
    Oncology (Williston Park); 2008 Oct; 22(11):1270-6. PubMed ID: 18980024
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma.
    Adams AL; Eltoum I; Krontiras H; Wang W; Chhieng DC
    Breast J; 2008; 14(2):141-6. PubMed ID: 18248553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.
    Bhargava R; Beriwal S; Dabbs DJ; Ozbek U; Soran A; Johnson RR; Brufsky AM; Lembersky BC; Ahrendt GM
    Cancer; 2010 Mar; 116(6):1431-9. PubMed ID: 20131351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options.
    Gentilini O; Masullo M; Rotmensz N; Peccatori F; Mazzarol G; Smeets A; Simsek S; De Dosso S; Veronesi P; Intra M; Zurrida S; Viale G; Goldhirsch A; Veronesi U
    Eur J Surg Oncol; 2005 Apr; 31(3):232-6. PubMed ID: 15780556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between Notch-2, Akt-1 and HER2/neu expression in invasive human breast cancer: a tissue microarray immunophenotypic analysis on 98 patients.
    Florena AM; Tripodo C; Guarnotta C; Ingrao S; Porcasi R; Martorana A; Lo Bosco G; Cabibi D; Franco V
    Pathobiology; 2007; 74(6):317-22. PubMed ID: 18087195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings.
    Alvarado-Cabrero I; Alderete-Vázquez G; Quintal-Ramírez M; Patiño M; Ruíz E
    Ann Diagn Pathol; 2009 Jun; 13(3):151-7. PubMed ID: 19433292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
    Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
    Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
    Precht LM; Lowe KA; Atwood M; Beatty JD
    Breast J; 2010; 16(4):362-8. PubMed ID: 20443786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept.
    Iwata H
    Breast Cancer; 2011 Apr; 18(2):92-7. PubMed ID: 21140250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Japanese Breast Cancer Society Clinical Practice Guideline for pathological diagnosis of breast cancer.
    Horii R; Honma N; Ogiya A; Kozuka Y; Fukuda T; Yoshida M; Ohsumi S; Mukai H;
    Breast Cancer; 2015 Jan; 22(1):59-65. PubMed ID: 25022266
    [No Abstract]   [Full Text] [Related]  

  • 20. Accuracy of sentinel lymph node biopsy after neo-adjuvant chemotherapy in patients with locally advanced breast cancer and clinically positive axillary nodes.
    Canavese G; Dozin B; Vecchio C; Tomei D; Villa G; Carli F; Del Mastro L; Levaggi A; Rossello C; Spinaci S; Bruzzi P; Catturich A
    Eur J Surg Oncol; 2011 Aug; 37(8):688-94. PubMed ID: 21696914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.